This Article Full Text Full Text (PDF) All Versions of this Article: 90/6/3209    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fuleihan, G. E.-H. Articles by Shamseddine, A. Search for Related Content PubMed PubMed Citation Articles by Fuleihan, G. E.-H. Articles by Shamseddine, A. Related Collections Calcium and Bone Metabolism Female Endocrinology

Pamidronate in the Prevention of Chemotherapy-Induced Bone Loss in Premenopausal Women with Breast Cancer: A Randomized Controlled Trial

Calcium Metabolism and Osteoporosis Program (G.E.-H.F., M.S.), Division of Endocrinology; Division of Hematology and Oncology (Y.A.M., A.C., Z.S., A.S.), School of Medicine; and Department of Epidemiology and Population Health (Z.M.), School of Health Sciences, American University of Beirut-Medical Center, Lebanon 113-6044

Address all correspondence and requests for reprints to: Ghada El-Hajj Fuleihan, M.D., M.P.H., Calcium Metabolism and Osteoporosis Program, American University of Beirut-Medical Center, Bliss Street, Beirut, Lebanon, 113-6044. E-mail: gf01{at}aub.edu.lb.

Purpose: Mortality from breast cancer has decreased in large part because of adjuvant chemotherapy. Sequelae of therapy include ovarian failure and bone loss, loss that would increase these patients’ risk of fracture with aging. In this study, we assessed the efficacy of pamidronate in preventing such loss.

Patients and Methods: The study was a 1-yr randomized, double-blind, placebo-controlled trial comparing pamidronate 60 mg iv every 3 months with placebo in 40 premenopausal women with newly diagnosed breast cancer. Bone mineral density (BMD) of the spine and hip and remodeling markers were monitored over 1 yr.

Results: Over half of the subjects became amenorrheic, and those who did were 4 yr older than those who did not (P = 0.02). The mean difference in percent change in BMD at 12 months between the two treatment groups was 5.1% at the lumbar spine (P = 0.002) in the overall study group and 5% at the lumbar spine and 5.2% at the total hip in the amenorrheic subgroup (P < 0.03). Biochemical markers of bone remodeling did not differ between the two treatment groups, and treatment was well tolerated.

Conclusion: Chemotherapy-induced amenorrhea is common with ensuing bone loss at the spine and hip. Pamidronate prevented bone loss at the spine and hip and was well tolerated.

This article has been cited by other articles:

				J. R. Gralow Bone Density in Breast Cancer: When to Intervene? J. Clin. Oncol., August 1, 2007; 25(22): 3194 - 3197. [Full Text] [PDF]

				R. Eastell Breast Cancer and the Risk of Osteoporotic Fracture: A Paradox J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 42 - 43. [Full Text] [PDF]

				S. L. Greenspan, R. K. Bhattacharya, S. M. Sereika, A. Brufsky, and V. G. Vogel Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 131 - 136. [Abstract] [Full Text] [PDF]